Adinazolam
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Adinazolam.svg | |
| Image:Adinazolam3d.png | |
| Adinazolam
| |
| Systematic (IUPAC) name | |
| 1-(8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,5-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine | |
| Identifiers | |
| CAS number | |
| ATC code | N05 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C19H18ClN5 |
| Mol. mass | 351.8 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic |
| Half life | < 3 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Schedule IV(US) |
| Routes | Oral |
Adinazolam (Deracyn®) is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative, and antidepressant[1] properties. Adinazolam was developed by Dr. Jackson B. Hester, who was seeking to enhance the antidepressant properties of alprazolam, which he also developed.[1]
Contents |
Pharmacology
Adinazolam produces inhibitory effects by binding to GABA receptors. This increases the effects of GABA.
Metabolism
Adinazolam was reported to have active metabolites in the August 1984 issue of The Journal of Pharmacy and Pharmacology.[1] The main metabolite is N-desmethyladinazolam.[1] The other two metabolites are alpha-hydroxyalprazolam and estazolam.[1] In the August 1986 issue of that same journal, Sethy, Francis and Day reported that proadifen inhibited the formation of N-desmethyladinazolam.[1]
Indications
Adinazolam is indicated as a treatment for anxiety and status epilepticus.
References
 | This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |
